Serum Lp-PLA2 Level Predicting Coronary Artery Lesions in Children with Kawasaki Disease
Keywords:Kawasaki disease, coronary artery lesions, lipoprotein associated phospholipase A2
Background: Kawasaki disease (KD) is an inflammatory disease associated with coronary vasculitis in children. In this study, we explored the correlation between Lipoprotein associated phospholipase A2 (Lp-PLA2) and coronary artery lesions (CAL) in children with KD.
Methods: Ninety-three children with KD were divided into a normal coronary artery (NCA, 54 cases) group and coronary artery lesions (CAL, 39 cases) group, according to the results of echocardiography. Another 42 healthy children were selected as the control group. The serumal levels of Lp-PLA2, Interferon-γ(IFN-γ) and Interleukin-6 (IL-6) were determined by using an enzyme-linked immunosorbent assay. In addition, erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level were analyzed. The left main coronary artery (LMCA), diameters of left anterior descending coronary artery (LADC), right proximal coronary artery (PRCA), and carotid intima-media thickness (IMT) were obtained by color Doppler ultrasound. The correlation between the above indexes and KD was analyzed.
Results: The levels of white blood cell counts (WBC), ESR, CRP, IFN-γ, IL-6 and Lp-PLA2 as well as IMT were significantly increased in KD children (P < 0.05), and the levels of CRP, IFN-γ, IL-6 and Lp-PLA2 as well as IMT in the CAL group increased more significantly (P < 0.05). An increasing trend also has been described in the diameters of LMCA, LADC and PRCA for KD children with CAL compared with with NCA. The results of logistic regression analysis showed that the elevated levels of CRP, IFN-γ, IL-6 and Lp-PLA2 were independent risk factors for KD with CAL. Correlation analysis showed that Lp-PLA2 level was positively correlated with the levels of IFN-γ, IL-6 and CRP in CAL group and NCA group (respectively, all P < 0.01). In addition, a similar correlation was also described between Lp-PLA2 level and the diameters of LMCA, LADC and PRCA in CAL group (respectively, all P < 0.01).
Conclusion: Lp-PLA2 may participate in the pathological mechanism of KD. Detection of the serum Lp-PLA2 level can be used in the diagnosis of KD disease and the assessment of coronary artery lesions in KD children.
Acosta S, Taimour S, Gottsater A, et al. 2017. Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: A prospective longitudinal cohort study. Atherosclerosis. 262: 14-18.
Amano S, Hazama F, Hamashima Y. 1979. Pathology of Kawa-saki disease: I. Pathology and morphogenesis of the vascular changes. Jpn Circ. J 43: 633-643.
Biscetti F, Nardella E, Bonadia N, et al. 2019. Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease. Cardiovasc Diabetol. 1:74.
Chen AD, Wang CL, Qin Y, et al. 2017. The effect of Danshen extract on lipoprotein-associated phospholipase A2 levels in patients with stable angina pectoris: study protocol for a randomized controlled trial - the DOLPHIN study. Trials. 18: 606.
Choi WG, Prasad M, Lennon R, et al. 2018. Chronic darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: A randomized-controlled study. Coron Artery Dis. 2:104-113.
Hedrich CM, Schnabel A, Hospach T. 2018. Kawasaki Disease. Front Pediatr. 6: 198.
Herrmann J, Mannheim D, Wohlert C, et al. 2009. Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J. 23:2930–8.
Huang YH, Hsu YW, Lu HF, et al. 2016. Interferon-gamma Genetic Polymorphism and Expression in Kawasaki Disease. Medicine (Baltimore). 17:e3501.
Kobayashi N, Mori M, Kobayashi Y, et al. 2004. Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease. Mod Rheumatol. 14:447-452.
Kobayashi T, Inoue Y, Takeuchi K, et al. 2006. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 22:2606-2612.
Kolodgie FD, Burke AP, Skorija KS, et al. 2006. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 11:2523-9.
Lehtinen L, Vainio P, Wikman H, et al. 2017. PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. J Pathol Clin Res. 2:123-138.
Leung DY, Geha RS, Newburger JW. et al. 1986. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J. Exp. Med. 164:1958-1972.
Liu XQ, Huang GY, Liang XC, et al. 2007. The study of vascular lesion using ultrasound in children with a history of Kawasaki disease. Zhonghua Yi Xue Za Zhi. 30: 2117-20.
Macphee CH, Nelson J, Zalewski A. 2006. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2: 154-161.
Matsubara T, Ichiyama T, Furukawa S. 2005. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin. Exp. Immunol. 141: 381-387.
McCrindle BW, Cifra B. 2018. The role of echocardiography in Kawasaki disease. Int J Rheum Dis. 21:50-55.
McCrindle BW, Rowley AH, Newburger JW, et al. 2017. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 17: e927- e999.
Meena RS, Rohit M, Gupta A, et al. 2014. Carotid intima-media thickness in children with Kawasaki disease. Rheumatol Int, 8: 1117-1121.
Menikou S, Langford PR, Levin M. 2019. Kawasaki disease: the role of immune complexes revisited. Front Immunol. 10: 1156.
Munzel T, Gori T. 2009. Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability. Eur Heart J. 23: 2829-2831.
Nakamura Y, Yashiro M, Uehara R, et al. 2010. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J. Epidemiol. 20: 302-307.
Naoe S, Takahashi K, Masuda H, et al. 1991. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 41:785-797.
Noto N, Okada T, Karasawa K, et al. 2009. Age-related acceleration of endothelial dysfunction and subclinical atherosclerosis in subjects with coronary artery lesions after Kawasaki disease. Pediatr Cardiol. 30: 262-268.
Poznyak AV, Zhang DW, Orekhova V, et al. 2020. A brief overview of currently used atherosclerosis treatment approaches targeting lipid metabolism alterations. Am J Cardiovasc Dis. 2:62–71.
Siddiqui MK, Kennedy G, Carr F, et al. 2018. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia. 6:1344-1353.
Takahashi K, Oharaseki T, Yokouchi Y, et al. 2007. Kawasaki disease arteritis and polyarteritis nodosa. Pathol Case Rev. 12:193-199.
Tsuda E, Tsujii N, Kimura K, et al. 2017. Distribution of Kawasaki Disease coronary artery aneurysms and the relationship to coronary artery diameter. Pediatr Cardiol. 38:932–940.
Wang HL, Zhang N, Li GR, et al. 2019. Proinflammatory cytokine IFN-γ, lncRNA BANCR and the occurrence of coronary artery disease. Life Sciences. 231:116510.
Wang Y, Qian SY, Yuan Y, et al. 2020. Do cytokines correlate with refractory Kawasaki disease in children? Clinica Chimica Acta. 506:222–227.
Xue M, Wang J. 2020. Utility of color Doppler echocardiography combined with clinical markers in diagnosis and prediction of prognosis of coronary artery lesions in Kawasaki disease. Exp Ther Med. 19:2597-2603.
Yandie Li, Qi Zheng, Lixia Zou, et al. 2019. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatr Rheumatol Online J. 1:1.
Zalewski A, Macphee C. 2005. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 5: 923-931.
Zhang DF, Liu LJ, Huang XP, et al. 2020. Insights Into Coronary Artery Lesions in Kawasaki Disease. Front Pediatr. 8:493.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).